

What is ReceptivaDx?

ReceptivaDx is an endometrial biopsy based on proprietary analysis of the endometrial lining providing unique and powerful information for patients experiencing unexplained infertility, recurrent pregnancy loss and previously undetected endometriosis.

Benefits of ReceptivaDx Testing

- Identifies potential issues often overlooked in standard fertility and pain evaluations
- Most reliable detection method for endometriosis, including superficial endometriosis left undetected via MRI or ultrasound
- Ensures timely access to appropriate treatment
- Can help guide initial patient management before potential referrals to fertility or endometriosis specialists

Power of ReceptivaDx

ReceptivaDx is the only test capable of identifying all major forms of uterine inflammation in a single biopsy.

ReceptivaDx Testing Includes:

- **BCL6 Marker:** Indicates uterine inflammation most often associated with previously undetected endometriosis
- **CD 138 Marker:** Gold standard for diagnosis of endometritis and bacterial inflammation



Why It Matters

Combined with a complete pathology analysis, women's healthcare providers in any clinical setting can now access powerful information that can expedite fertility treatment decisions and/or uncover conditions such as endometriosis that historically have taken 7-10 years to properly diagnose.

ReceptivaDx Testing Includes:

- **BCL6 Biomarker:**
Inflammation most often linked to previously undetected endometriosis
- **Pathology Review:**
Confirms cycle phase, assesses tissue adequacy/architecture, detects polyps, and potentially cancerous hyperplasia and other abnormalities
- **CD138 (Add-on):**
Detects chronic endometritis, a treatable infection associated with infertility and recurrent pregnancy loss

Biopsy Information

- 7-10 days post ovulation
- Standard endometrial biopsy
- Room temperature transport
- Results within 10 business days

ReceptivaDx collection kits include 10% formalin vial and all necessary pre-paid shipping materials for delivery to our US based lab facilities.

Pricing

ReceptivaDx: **\$690**

Add CD138: **\$145**

(Includes biopsy kit & overnight shipment)

Cicero Diagnostics is a fee for service provider and does not bill or contract with insurance. Reimbursement can be achieved via self-submission claim using detailed receipt provided by Cicero Diagnostics. Provider must provide ICD10 code on test requisition.

To Order Collection Kits:

Call: 800-795-5385 | Fax: 714-475-1533

Email: info@receptivadx.com

Scan QR Code for More Information:



 **Cicero Diagnostics**



ReceptivaDx

ADVANCEMENTS IN TESTING FOR



Unexplained Infertility



Recurrent Pregnancy Loss



**Suspected Endometriosis/
Undiagnosed Pain**



Cicero Diagnostics

The global leader in endometrial analysis
and early endometriosis detection



How Cicero Diagnostics Became the Global Leader in Endometrial Analysis and Endometriosis Detection

- Developed first non-invasive proprietary test to identify uterine lining inflammation
- Developed first and only non-invasive proprietary test to detect endometriosis with 93% sensitivity and 96% specificity
- Over 25 peer-reviewed publications
- Over 50,000 endometrial analyses performed
- Global support and acknowledgment of leading fertility specialists and minimally invasive gynecologic surgeons

For Patients with Unexplained Infertility & Recurrent Pregnancy Loss

ReceptivaDx is now available for women with fertility issues desiring answers prior to a fertility specialist referral and for women not considering IVF.

By providing a unique analysis of the uterine lining, healthcare providers can resolve issues in a timely manner, saving many patients time, money and potentially eliminating the need for outside referrals.

Since 2017, ReceptivaDx has been a trusted tool used by advanced fertility centers in the US and in over 24 countries worldwide to access answers concerning failed implantation and pregnancy loss.

Candidates for Testing:

- Unexplained infertility
- Surrogate testing
- Recurrent pregnancy loss
- Family history of endometriosis

Actionable ReceptivaDx Test Results

Positive BCL6 Result:

Indicates presence of uterine inflammation, a leading cause of unexplained infertility and recurrent pregnancy loss.

Proven treatment pathways include hormone suppression or surgical intervention. Treatments have potential to reduce unnecessary referrals for IVF. Published treatment protocols have been proven to reduce first trimester losses in absence of genetic abnormalities.

Negative BCL6 Result:

Eliminates uterine lining as most likely cause of fertility issues. Reduces chances of endometriosis to less than 7% as potential cause of fertility issues.

For Patients with Undiagnosed Pain/Suspected Endometriosis

Until ReceptivaDx, the women's healthcare field has lacked a test that could assist in triaging patients with undiagnosed pelvic or abdominal pain. ReceptivaDx testing has proven to be a powerful predictor of endometriosis that can be performed during a routine office visit allowing for expedited referrals to endometriosis specialists for an official diagnosis and a proper treatment plan.

Candidates for Testing:

- Family history of endometriosis
- Undiagnosed pelvic or abdominal pain
- Pain during and after sex
- Recurrent bladder or bowel pain
- High Body Mass Index (BMI)

Actionable ReceptivaDx Test Results

Positive BCL6 Result:

96% probability that endometriosis will be detected via laparoscopy.

Negative BCL6 Result:

Less than 7% chance of endometriosis being found via laparoscopy.